nejm semaglutide heart failure STEP-HFpEF Trial

In patients with heart failure with preserved ejection fraction and obesity, but without type 2 diabetes, semaglutide treatment has led to larger reductions in heart failure–related symptoms and physical limitations and greater

25.87

★★★★☆4.8 (126)

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

23.22

★★★★★4.9 (98)

NEJM - A secondary analysis of the SOUL trial showed that oral semaglutide, like the injected form, improves outcomes related to heart failure in high-risk patients with diabetes

25.43

★★★★★5.0 (157)

SELECT Trial

25.23

★★★★★4.7 (84)

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF

21.70

★★★★★4.9 (203)

nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential

23.98

★★★★★5.0 (176)

In patients with cardiovascular disease and overweight or obesity but no diabetes, semaglutide was superior to placebo in lowering the risk of major adverse cardiovascular events at a mean follow-up of 39.8

24.73

★★★★★4.8 (132)